Related Experiment Video

Updated: Aug 9, 2026

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease

K Wada, A Nakajima, R S Blumberg

    Trends in Molecular Medicine
    |August 23, 2001
    PubMed

    Insights

    Peroxisome proliferator-activated receptor gamma (PPARgamma) is crucial for fat cell differentiation and insulin sensitivity. New research shows PPARgamma also protects against intestinal inflammation and immune-related tissue damage, highlighting its therapeutic potential.

    Area of Science:

    • Molecular biology
    • Immunology
    • Endocrinology

    Background:

    • Peroxisome proliferator-activated receptor gamma (PPARgamma) is a nuclear receptor vital for adipocyte differentiation and insulin sensitivity.
    • Emerging evidence implicates PPARgamma in modulating inflammatory responses within the gastrointestinal tract.

    Discussion:

    • PPARgamma activation demonstrates significant anti-inflammatory effects in animal models of intestinal inflammation.
    • The receptor plays a protective role against tissue injury induced by immune system activation in the gut.
    • These findings suggest PPARgamma acts as a key mediator in resolving inflammatory processes.

    Key Insights:

    • PPARgamma inhibits tissue injury linked to immune activation during intestinal inflammation.
    • The nuclear receptor exhibits potent anti-inflammatory properties beyond its metabolic functions.
    • PPARgamma represents a promising therapeutic target for inflammatory conditions.

    Outlook:

    • Further investigation into PPARgamma's mechanisms in intestinal immunity is warranted.
    • Targeting PPARgamma may offer novel therapeutic strategies for inflammatory bowel diseases.
    • Exploring PPARgamma agonists could lead to treatments for immune-mediated tissue damage.

    More Related Videos

    Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis08:58

    Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

    Published on: January 5, 2017

    Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis09:44

    Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

    Published on: October 14, 2025

    Related Concept Videos

    Drugs for Treatment of Ulcerative Colitis in IBD01:29

    Drugs for Treatment of Ulcerative Colitis in IBD

    Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
    Inflammatory Bowel Disease IV: Pharmacological Management01:29

    Inflammatory Bowel Disease IV: Pharmacological Management

    Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
    Pharmacologic...
    Inflammatory Bowel Disease II: Ulcerative Colitis01:20

    Inflammatory Bowel Disease II: Ulcerative Colitis

    Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
    Inflammatory Bowel Disease III: Crohn's Disease01:25

    Inflammatory Bowel Disease III: Crohn's Disease

    Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...